• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by HTG Molecular Diagnostics Inc. (Amendment)

    2/10/23 9:03:52 AM ET
    $HTGM
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $HTGM alert in real time by email
    SC 13G/A 1 d9937915_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    HTG Molecular Diagnostics, Inc.
    (Name of Issuer)

     

     

    Common Stock, $0.001 par value per share
    (Title of Class of Securities)

     

     

    40434H203
    (CUSIP Number)

     

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     


    CUSIP No.
    40434H203    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Samjo Capital, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [  ]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      0  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      0  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      0  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     
     
     

     


    CUSIP No.
    40434H203    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Samjo Management, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [  ]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      0  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      0  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      0  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, OO

     

     

     
     

     


    CUSIP No.
    40434H203    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Andrew N. Wiener  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [  ]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      0  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      0  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      0  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

     
     

     

    CUSIP No. 40434H203    

     

    Item 1. (a). Name of Issuer:  
           
        HTG Molecular Diagnostics, Inc.  
           
      (b). Address of issuer's principal executive offices:  
           
       

    3430 E. Global Loop

    Tucson, Arizona 85706

     
           
    Item 2. (a). Name of person filing:  
           
       

    This statement is filed by:

     

     
        (i) Samjo Capital, LLC, a Delaware limited liability company ("Samjo Capital");
           
        (ii)

    Samjo Management, LLC, a Delaware limited liability company ("Samjo Management"); and

     

        (iii) Andrew N. Wiener, an individual (collectively with Samjo Capital and Samjo Management, the "Reporting Persons").
           
      (b). Address or principal business office or, if none, residence:  
           
       

    The address of the principal office of the Reporting Persons is:

     

    599 Lexington Avenue, 21st Floor, New York, NY 10022

     

     
           
      (c). Citizenship:  
           
       

    Samjo Capital and Samjo Management are Delaware limited liability companies. Mr. Wiener is a U.S. Citizen.

     

     
           
      (d). Title of class of securities:  
           
        Common Stock, $0.001 par value per share  
           
      (e). CUSIP No.:  
           
        40434H203  
               

     

    Item 3. If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a:

     

    Not Applicable

     
     

     

    CUSIP No. 40434H203    

     

    Item 4. Ownership.

     

      (a) Amount beneficially owned:
         
       

    Samjo Capital is the beneficial owner of 0 shares of Common Stock, par value $0.001 ("Common Stock").

    Samjo Management is the beneficial owner of 0 shares of Common Stock.

    Andrew N. Wiener is the beneficial owner of 0 shares of Common Stock.

     

      (b) Percent of class:
         
       

    Samjo Capital beneficially owns 0% of the Issuer's Common Stock.

    Samjo Management beneficially owns 0% of the Issuer's Common Stock.

    Andrew N. Wiener beneficially owns 0% of the Issuer's Common Stock.

     

      (c) Number of shares as to which the person has:
         

     

        (i) Sole power to vote or to direct the vote  
             
          Samjo Capital 0
             
          Samjo Management 0
             
          Andrew N. Wiener 0
             

     

        (ii) Shared power to vote or to direct the vote  
             
          Samjo Capital 0
             
          Samjo Management 0
             
          Andrew N. Wiener 0
             

     

        (iii) Sole power to dispose or to direct the disposition of  
             
          Samjo Capital 0
             
          Samjo Management 0
             
          Andrew N. Wiener 0
             

     

     
     

     

     

        (iv) Shared power to dispose or to direct the disposition of  
             
          Samjo Capital 0
             
          Samjo Management 0
             
          Andrew N. Wiener 0
             

     

     

     

    In addition to his role as the sole Managing Member of Samjo Capital and Samjo Management, Mr. Wiener is also one of the portfolio managers of the CPA Samjo Investment Program ("SI") employed by Cowen Prime Advisors LLC ("CPA"). The clients of Samjo Management and Samjo Capital employ investment strategies that are similar to those employed in the CPA SI program. Samjo Capital, Samjo Management and their clients are not affiliated with CPA and Mr. Wiener does not have beneficial ownership over the shares held in the CPA SI program except for shares held in accounts owned by Mr. Wiener and his immediate family members. As a result, Samjo Capital and Samjo Management do not make joint filings with respect to any shares of the issuer held by any CPA clients except with respect to shares held in accounts owned by Mr. Wiener and his immediate family members. To the best of Samjo Capital's, Samjo Management's and Mr. Wiener's knowledge and belief, CPA reports the ownership of shares by such CPA clients separately to the extent required and is identified as the reporting person. 

     

    Instruction: For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

       

     

     
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  [X]*.
       
      This final amendment reflects that each reporting person has ceased to be the beneficial owner of more than five percent of the Common Stock of the issuer.
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      Not Applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      Not Applicable
       
    Item 8. Identification and Classification of Members of the Group.
       
      Not Applicable
       
    Item 9. Notice of Dissolution of Group.
       
      Not Applicable
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

    Exhibits: Exhibit: Joint Acquisition Statement.

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

      February 10, 2023
      (Date)
       
      SAMJO CAPITAL, LLC
       
      /s/ Andrew N. Wiener
      (Signature)
       
     

     

    Andrew N. Wiener, Managing Member

      (Name/Title)

     

     

     

      February 10, 2023
      (Date)
       
      SAMJO MANAGEMENT, LLC
       
      /s/ Andrew N. Wiener
      (Signature)
       
       
       
      Andrew N. Wiener, Managing Member
      (Name/Title)
       
     

     

     

      February 10, 2023
      (Date)
       
       
      /s/ Andrew N. Wiener
      (Signature)
       
       
      Andrew N. Wiener
      (Name/Title)
       
       
       

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

     

    EXHIBIT

     

     

    JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k)

     

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

      February 10, 2023
      (Date)
       
      SAMJO CAPITAL, LLC
       
      /s/ Andrew N. Wiener
      (Signature)
       
     

     

    Andrew N. Wiener, Managing Member

      (Name/Title)

     

     

      February 10, 2023
      (Date)
       
      SAMJO MANAGEMENT, LLC
       
      /s/ Andrew N. Wiener
      (Signature)
       
       
       
      Andrew N. Wiener, Managing Member
      (Name/Title)
       
       
      February 10, 2023
      (Date)
       
       
       
      /s/ Andrew N. Wiener
      (Signature)
       
       
      Andrew N. Wiener, Managing Member
      (Name/Title)

     

     

    Get the next $HTGM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HTGM

    DatePrice TargetRatingAnalyst
    1/7/2022$5.00 → $8.00Hold → Buy
    Craig-Hallum
    More analyst ratings

    $HTGM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention

      TUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization (BIO) International Convention and will host in-person meetings during the remaining days of the June 5 – 8, 2023 event in Boston, MA. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG's objective is to develop best-in-class molecules for the treat

      5/18/23 8:00:00 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Highlights the Advantages of Its Drug Discovery Engine

      TUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG's objective is to develop best-in-class molecules for the treatment of diseases, with the ability to apply its platform agnostically across therapy areas. At the center of this approach is HTG's proprietary RNA profiling technologies, functionally married with an adva

      5/16/23 8:47:40 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights

      TUCSON, Ariz., May 10, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights. HTG has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. At the center of this approach is the application of HTG's proprietary RNA profiling technologies, functionally married with advanced medicinal chemistry using a novel artificial intelligence ("AI")-driven platform. This unique drug can

      5/10/23 5:51:27 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HTGM
    SEC Filings

    See more
    • HTG Molecular Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)

      6/8/23 4:51:32 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Molecular Diagnostics Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update

      8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)

      6/5/23 3:42:54 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Molecular Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)

      5/24/23 5:01:07 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HTGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HTG Molecular Diagnostics upgraded by Craig-Hallum with a new price target

      Craig-Hallum upgraded HTG Molecular Diagnostics from Hold to Buy and set a new price target of $8.00 from $5.00 previously

      1/7/22 10:15:02 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SVB Leerink reiterated coverage on HTG Molecular Diagnostics with a new price target

      SVB Leerink reiterated coverage of HTG Molecular Diagnostics with a rating of Outperform and set a new price target of $10.00 from $15.00 previously

      5/14/21 6:42:26 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HC Wainwright & Co. reiterated coverage on HTG Molecular Diagnostics with a new price target

      HC Wainwright & Co. reiterated coverage of HTG Molecular Diagnostics with a rating of Buy and set a new price target of $9.00 from $11.00 previously

      5/14/21 6:28:53 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HTGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Barat Stephen

      4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)

      6/9/23 8:11:23 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Barat Stephen

      4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)

      4/7/23 4:16:01 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 3: New insider Barat Stephen claimed ownership of 1,361 shares

      3 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)

      2/10/23 4:34:09 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HTGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by HTG Molecular Diagnostics Inc. (Amendment)

      SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)

      2/13/23 3:33:23 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by HTG Molecular Diagnostics Inc. (Amendment)

      SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)

      2/10/23 9:03:52 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by HTG Molecular Diagnostics Inc.

      SC 13G - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)

      2/3/23 4:02:18 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HTGM
    Financials

    Live finance-specific insights

    See more
    • HTG Announces Certain Preliminary 2022 Unaudited Financial Results

      Preliminary full year 2022 unaudited revenue of $6.4 million Cash and cash equivalents of $12.2 million as of December 31, 2022 TUCSON, Ariz., Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022. Total revenue for the full year 2022 is expected to be approximately $6.4 million, including approximately $2.7 million of HTG Transcriptome Panel (HTP) revenue representing 42% of our total revenue. Cash and cash

      1/6/23 8:00:00 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Molecular Diagnostics Reports Second Quarter 2022 Results

      TUCSON, Ariz., Aug. 11, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business highlights and financial results for the quarter ended June 30, 2022. Throughout the quarter ended June 30, 2022, the Company's technology and strategic development efforts were highlighted in a number of customer and KOL presentations and publications including, but not limited to, the following: A webinar titled "Integration of the HTG Transcriptome Panel into Preclinical and Clinical Programs to Drive Precision Medicine Research" fe

      8/11/22 4:05:00 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Molecular Diagnostics to Announce Q2 2022 Financial Results and Host Conference Call on Thursday, August 11

      TUCSON, Ariz., Aug. 04, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the quarter ended June 30, 2022 after the market close on Thursday, August 11, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time. Details for the conference call are as follows: Conference Call & Webcast Details Date:Thursday, August 11Time:4:30pm ETToll Free:1-800-954-0602 International:1-212-231-2936 Conference ID:2

      8/4/22 8:00:00 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials